Bionano Genomics, Inc. 8-K

What Happened
Bionano Genomics, Inc. filed a Form 8-K (Item 5.02) on June 5, 2026, reporting that Alka Chaubey, Ph.D. resigned as Chief Medical Officer on June 2, 2026, with the resignation effective July 5, 2026. The report was signed by Albert A. Luderer, Ph.D., Interim Chief Executive Officer.

Key Details

• Filing: Form 8-K filed June 5, 2026 (Item 5.02 — Departure of Certain Officers).
• Resignation date: Alka Chaubey, Ph.D. resigned on June 2, 2026; effective July 5, 2026.
• Signatory: Report signed by Albert A. Luderer, Ph.D., Interim CEO.
• The 8-K does not provide further details on a successor, reason for the departure, or any related agreements.

Why It Matters
A change in the chief medical officer is a material leadership change because the CMO typically oversees clinical development and medical strategy. Investors should watch for follow-up disclosures about a successor or any potential impact on clinical programs, regulatory communications, or timelines for product development.